Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- SymBio Decides on Its First Development Product
January 9, 2006
- BUSINESS NEWS IN BRIEF
January 9, 2006
- Bayer Receives "Low Carbon Leaders Award"
January 9, 2006
- R&D NEWS IN BRIEF
January 9, 2006
- SEMINAR
January 9, 2006
- NEW PRODUCTS
January 9, 2006
- 3 Associations Draft Proposal on Med. Device Safety Management
January 9, 2006
- STATISTICS
January 9, 2006
- ACCJ Calls For Improvement in Review of Medical Devices
January 9, 2006
- ＜New Year's Greeting＞PhRMA to Work to More Quickly Bring Innovative Drugs to Patients
January 9, 2006
- MEDICAL DEVICE NEWS IN BRIEF
January 9, 2006
- Surprise Free Forecasts For 2006
January 9, 2006
- REGULATORY NEWS IN BRIEF -2-
December 26, 2005
- Blopress Retains No. 1 Ranking, Lipitor Takes No. 2 Spot
December 26, 2005
- Takeda Becomes Alfresa HD's Top Supplier
December 26, 2005
- BUSINESS NEWS IN BRIEF
December 26, 2005
- SSP's Consumer Healthcare Division Targeting Female Consumers
December 26, 2005
- Subcommittee Approves Recommendations on Sale of OTC Drugs
December 26, 2005
- Tailor-made Bone That Can Be Shaped in Any Form Developed by UT Group
December 26, 2005
- Drugs, Medical Materials to See 1.8% Price Cut on the Basis of Medical Expenditure
December 26, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…